290382792019041620191210
1098-65966212018JanAntimicrobial agents and chemotherapyAntimicrob Agents ChemotherA CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.e01483-1710.1128/AAC.01483-17A strain of the opportunistic pathogenic yeast Candida lusitaniae was genetically modified for use as a cellular model for assessing by allele replacement the impact of lanosterol C14α-demethylase ERG11 mutations on azole resistance. Candida lusitaniae was chosen because it is susceptible to azole antifungals, it belongs to the CTG clade of yeast, which includes most of the Candida species pathogenic for humans, and it is haploid and easily amenable to genetic transformation and molecular modeling. In this work, allelic replacement is targeted at the ERG11 locus by the reconstitution of a functional auxotrophic marker in the 3' intergenic region of ERG11 Homologous and heterologous ERG11 alleles are expressed from the resident ERG11 promoter of C. lusitaniae, allowing accurate comparison of the phenotypic change in azole susceptibility. As a proof of concept, we successfully expressed in C. lusitaniae different ERG11 alleles, either bearing or not bearing mutations retrieved from a clinical context, from two phylogenetically distant yeasts, C. albicans and Kluyveromyces marxianusCandida lusitaniae constitutes a high-fidelity expression system, giving specific Erg11p-dependent fluconazole MICs very close to those observed with the ERG11 donor strain. This work led us to characterize the phenotypic effect of two kinds of mutation: mutation conferring decreased fluconazole susceptibility in a species-specific manner and mutation conferring fluconazole resistance in several yeast species. In particular, a missense mutation affecting amino acid K143 of Erg11p in Candida species, and the equivalent position K151 in K. marxianus, plays a critical role in fluconazole resistance.Copyright © 2017 American Society for Microbiology.AccoceberryIsabelleIUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France.University Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, CHU Bordeaux, Bordeaux, France.RougeronAmandineAUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France.University Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, CHU Bordeaux, Bordeaux, France.BiteauNicolasNUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France.ChevrelPaulinePUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France.Fitton-OuhabiValérieVUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France.NoëlThierryTUniversity Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, Bordeaux, France thierry.noel@u-bordeaux.fr.engJournal ArticleResearch Support, Non-U.S. Gov't20171221
United StatesAntimicrob Agents Chemother03150610066-48040Antifungal Agents8VZV102JFYFluconazoleEC 1.14.14.154Sterol 14-DemethylaseIMAntifungal AgentspharmacologyCandidaclassificationdrug effectsgeneticsDrug Resistance, FungalgeneticsFluconazolepharmacologyHumansMicrobial Sensitivity TestsMutationgeneticsPhylogenySterol 14-DemethylasegeneticsCandidaCandida lusitaniaeERG11 mutationKluyveromycesfluconazole resistanceheterologous expression201772020171012201710196020194176020171018602018621epublish29038279PMC574031910.1128/AAC.01483-17AAC.01483-17des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corm S, Lemaitre L, Poulain D, Yakoub-Agha I, Alfandari S, Sendid B. 2011. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther 36:152–160. doi: 10.1111/j.1365-2710.2010.01166.x.10.1111/j.1365-2710.2010.01166.x21366643Snelders E, van der Lee HAL, Kuijpers J, Rijs AJMM, Varga J, Samson RA, Mellado E, Donders ART, Melchers WJG, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219. doi: 10.1371/journal.pmed.0050219.10.1371/journal.pmed.0050219PMC258162318998768White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382–402.PMC1068389564569Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85. doi: 10.1016/S1473-3099(02)00181-0.10.1016/S1473-3099(02)00181-011901654Selmecki A, Forche A, Berman J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367–370. doi: 10.1126/science.1128242.10.1126/science.1128242PMC171702116857942Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell 3:1391–1397. doi: 10.1128/EC.3.6.1391-1397.2004.10.1128/EC.3.6.1391-1397.2004PMC53903215590814Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 3:1639–1652. doi: 10.1128/EC.3.6.1639-1652.2004.10.1128/EC.3.6.1639-1652.2004PMC53902115590837Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373–384. doi: 10.1016/j.diagmicrobio.2009.11.006.10.1016/j.diagmicrobio.2009.11.00620226328Lamb DC, Kelly DE, Schunck W-H, Shyadehi AZ, Akhtar M, Lowe DJ, Baldwin BC, Kelly SL. 1997. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 272:5682–5688. doi: 10.1074/jbc.272.9.5682.10.1074/jbc.272.9.56829038178Lamb DC, Kelly DE, White TC, Kelly SL. 2000. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 44:63–67. doi: 10.1128/AAC.44.1.63-67.2000.10.1128/AAC.44.1.63-67.2000PMC8962910602724Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241–253. doi: 10.1093/jac/42.2.241.10.1093/jac/42.2.241PMC1053959527767Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39:2378–2386. doi: 10.1128/AAC.39.11.2378.10.1128/AAC.39.11.2378PMC1629518585712Kontoyiannis DP, Sagar N, Hirschi KD. 1999. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 43:2798–2800.PMC8956410543768Dujon B. 2010. Yeast evolutionary genomics. Nat Rev Genet 11:512–524. doi: 10.1038/nrg2811.10.1038/nrg281120559329Santos MA, Tuite MF. 1995. The CUG codon is decoded in vivo as serine and not leucine in Candida albicans. Nucleic Acids Res 23:1481–1486. doi: 10.1093/nar/23.9.1481.10.1093/nar/23.9.1481PMC3068867784200Santos MAS, Gomes AC, Santos MC, Carreto LC, Moura GR. 2011. The genetic code of the fungal CTG clade. C R Biol 334:607–611. doi: 10.1016/j.crvi.2011.05.008.10.1016/j.crvi.2011.05.00821819941Couzigou C, Gabriel F, Biteau N, Fitton-Ouhabi V, Noël T, Accoceberry I. 2014. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia. Med Mycol Case Rep 5:12–15. doi: 10.1016/j.mmcr.2014.04.002.10.1016/j.mmcr.2014.04.002PMC405235724936404James TY, Kauff F, Schoch CL, Matheny PB, Hofstetter V, Cox CJ, Celio G, Gueidan C, Fraker E, Miadlikowska J, Lumbsch HT, Rauhut A, Reeb V, Arnold AE, Amtoft A, Stajich JE, Hosaka K, Sung GH, Johnson D, O'Rourke B, Crockett M, Binder M, Curtis JM, Slot JC, Wang Z, Wilson AW, Schüssler A, Longcore JE, O'Donnell K, Mozley-Standridge S, Porter D, Letcher PM, Powell MJ, Taylor JW, White MM, Griffith GW, Davies DR, Humber RA, Morton JB, Sugiyama J, Rossman AY, Rogers JD, Pfister DH, Hewitt D, Hansen K, Hambleton S, Shoemaker RA, Kohlmeyer J, Volkmann-Kohlmeyer B, Spotts RA, Serdani M, Crous PW, Hughes KW, Matsuura K, Langer E, Langer G, Untereiner WA, Lücking R, Büdel B, Geiser DM, Aptroot A, Diederich P, Schmitt I, Schultz M, Yahr R, Hibbett DS, Lutzoni F, McLaughlin DJ, Spatafora JW, Vilgalys R. 2006. Reconstructing the early evolution of Fungi using a six-gene phylogeny. Nature 443:818–822. doi: 10.1038/nature05110.10.1038/nature0511017051209Mühlhausen S, Kollmar M. 2014. Molecular phylogeny of sequenced Saccharomycetes reveals polyphyly of the alternative yeast codon usage. Genome Biol Evol 5:3222–3237.PMC498644625646540Durrens P, Klopp C, Biteau N, Fitton-Ouhabi V, Dementhon K, Accoceberry I, Sherman DJ, Noël T. 2017. Genome sequence of the yeast Clavispora lusitaniae type strain CBS. 6936. Genome Announc 5:e00724-17. doi: 10.1128/genomeA.00724-17.10.1128/genomeA.00724-17PMC554364128774979Boeke JD, Croute FL, Fink GR. 1984. A positive selection for mutants lacking orotidine-5′-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol Gen Genet 197:345–346. doi: 10.1007/BF00330984.10.1007/BF003309846394957Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FCS, Odds FC, Bossche HV. 1999. Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701–2713. doi: 10.1099/00221287-145-10-2701.10.1099/00221287-145-10-270110537192Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD. 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 59:450–460. doi: 10.1128/AAC.03470-14.10.1128/AAC.03470-14PMC429138525385095Favel A, Michel-Nguyen A, Datry A, Challier S, Leclerc F, Chastin C, Fallague K, Regli P. 2004. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother 53:526–529. doi: 10.1093/jac/dkh106.10.1093/jac/dkh10614963064Muzzey D, Schwartz K, Weissman JS, Sherlock G. 2013. Assembly of a phased diploid Candida albicans genome facilitates allele-specific measurements and provides a simple model for repeat and indel structure. Genome Biol 14:R97. doi: 10.1186/gb-2013-14-9-r97.10.1186/gb-2013-14-9-r97PMC405409324025428Löffler J, Kelly SL, Hebart H, Schumacher U, Lass-Flörl C, Einsele H. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151:263–268. doi: 10.1016/S0378-1097(97)00172-9.10.1016/S0378-1097(97)00172-99228762Xu Y, Chen L, Li C. 2008. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61:798–804. doi: 10.1093/jac/dkn015.10.1093/jac/dkn01518218640Delarze E, Sanglard D. 2015. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist Updat 23:12–19. doi: 10.1016/j.drup.2015.10.001.10.1016/j.drup.2015.10.00126690338MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother 49:1745–1752. doi: 10.1128/AAC.49.5.1745-1752.2005.10.1128/AAC.49.5.1745-1752.2005PMC108767815855491Marr KA, Lyons CN, Rustad T, Bowden RA, White TC. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42:2584–2589.PMC1059019756759White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46:1704. doi: 10.1128/AAC.46.6.1704-1713.2002.10.1128/AAC.46.6.1704-1713.2002PMC12724512019079Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell 11:1289–1299. doi: 10.1128/EC.00215-12.10.1128/EC.00215-12PMC348591422923048Xu Y, Sheng F, Zhao J, Chen L, Li C. 2015. ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates. Arch Microbiol 197:1087–1093. doi: 10.1007/s00203-015-1146-8.10.1007/s00203-015-1146-826349561Xisto MIDS, Caramalho RDF, Rocha DAS, Ferreira-Pereira A, Sartori B, Barreto-Bergter E, Junqueira ML, Lass-Flörl C, Lackner M. 2017. Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug? J Antimicrob Chemother 72:988–992.28065893Monk BC, Tomasiak TM, Keniya MV, Huschmann FU, Tyndall JD, O'Connell JD, Cannon RD, McDonald JG, Rodriguez A, Finer-Moore JS. 2014. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci U S A 111:3865–3870. doi: 10.1073/pnas.1324245111.10.1073/pnas.1324245111PMC395620524613931Hargrove TY, Friggeri L, Wawrzak Z, Qi A, Hoekstra WJ, Schotzinger RJ, York JD, Guengerich FP, Lepesheva GI. 2017. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J Biol Chem 292:6728–6743. doi: 10.1074/jbc.M117.778308.10.1074/jbc.M117.778308PMC539912028258218Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. 2002. Molecular basis of resistance to azole antifungals. Trends Mol Med 8:76–81. doi: 10.1016/S1471-4914(02)02280-3.10.1016/S1471-4914(02)02280-311815273Parker JE, Warrilow AGS, Price CL, Mullins JGL, Kelly DE, Kelly SL. 2014. Resistance to antifungals that target CYP51. J Chem Biol 7:143. doi: 10.1007/s12154-014-0121-1.10.1007/s12154-014-0121-1PMC418233825320648Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD. 2015. Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrob Agents Chemother 59:5942–5950. doi: 10.1128/AAC.01358-15.10.1128/AAC.01358-15PMC457609726169412Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother 56:4223–4232. doi: 10.1128/AAC.06253-11.10.1128/AAC.06253-11PMC342158122615281El-Kirat-Chatel S, Dementhon K, Noël T. 2011. A two-step cloning-free PCR-based method for the deletion of genes in the opportunistic pathogenic yeast Candida lusitaniae. Yeast 28:321–330. doi: 10.1002/yea.1836.10.1002/yea.183621456057Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed. CLSI document M27-A3 Clinical and Laboratory Standards Institute, Wayne, PA.François F, Chapeland-Leclerc F, Villard J, Noël T. 2004. Development of an integrative transformation system for the opportunistic pathogenic yeast Candida lusitaniae using URA3 as a selection marker. Yeast 21:95–106. doi: 10.1002/yea.1059.10.1002/yea.105914755635Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159.2440339Gouy M, Guindon S, Gascuel O. 2010. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 27:221–224. doi: 10.1093/molbev/msp259.10.1093/molbev/msp25919854763Gillum AM, Tsay EY, Kirsch DR. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198:179–182. doi: 10.1007/BF00328721.10.1007/BF003287216394964